Invion Ltd. · ASX:IVX
Invion — Investor Presentation (February 2022)
13 slides from Invion's investor presentation, Feb 3, 2022
Slide 1: ASX Announcement: Investor Presentation to Brokers and Institutional Investors
ASX ANNOUNCEMENT INVESTOR PRESENTATION TO BROKERS AND INSTITUTIONAL INVESTORS MELBOURNE (AUSTRALIA) 03 February 2022: Invion Limited (ASX: IVX) (“Invion” or the For personal use only “Company”) would like to release the attached investor presentation, which Invion will be using at meetings with brok
Slide 2: Investor Presentation February 2022
For personal use only INVESTOR PRESENTATION February 2022
Slide 3: Developing Photosoft Technology: The Next-Generation Photodynamic Therapy
DEVELOPING PHOTOSOFTTM TECHNOLOGY THE NEXT-GENERATION PHOTODYNAMIC THERAPY (PDT) For personal use only § Major disease areas: Cancer, atherosclerosis, infectious diseases Meeting Clinical § Advancing Photosoft™ technology – novel PDT photosensitiser INV043 Needs § Collaboration with world class expe
Slide 4: Photodynamic Therapy: A Novel Cancer Treatment
PHOTODYNAMIC THERAPY: A NOVEL CANCER TREATMENT For personal use only Photodynamic therapy (PDT) Generates reactive oxygen Combines photosensitiser Direct cell death along with species (“ROS”) causing 1 compound with light- induced activation 2 damage to only targeted 3 induction of immune response c
Slide 5: Advantages of Photosoft Technology
ADVANTAGES OF PHOTOSOFT™ TECHNOLOGY For personal use only PDT is a proven cancer Absorbs light in wavelengths to therapy. Photosoft™ Selectively accumulates “light up” a tumour (diagnostic) technology has made in cancer cells and or generates reactive oxygen dramatic improvements and rapidly clears
Slide 6: Improved API: INV043 Key Characteristics
IMPROVED API1: INV043 KEY CHARACTERISTICS For personal use only A. INV043 Activity Against B. A. Multiple Cancer Cell INV043 Types Activity Against Active against multiple cancers Highly potent and selective 100 Multiple Cancer Cell Types Viability (% of control) 100 • INV043 successfully regressed
Slide 7: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only § Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies § Proof of Concept (PoC) pilot showed complete regression of TNBC in vivo following INV043 treatment
Slide 8: New Market Opportunities: Expanded Territories and New Disease Areas
NEW MARKET OPPORTUNITIES EXPANDED TERRITORIES AND NEW DISEASE AREAS For personal use only Invion’s exclusive territories give access to markets with >2.8 billion people Cancer Funding Remains primary focus for Invion’s clinical development RMW Invion Australia and New Zealand Territory 100% 0% Expan
Slide 9: Partnerships: Leading Institutions
PARTNERSHIPS LEADING INSTITUTIONS For personal use only • Global bioscience medical research institute • World-class institute that combines its premier • Over 400 scientists focused on groundbreaking cancer research capability with its ability to discoveries addressing complex problems in translate
Slide 10: Management Team: Experienced Leadership
MANAGEMENT TEAM EXPERIENCED LEADERSHIP For personal use only THIAN CHEW MELANIE LEYDIN EXECUTIVE CHAIRMAN & CEO CFO • Managing Partner, Polar Ventures • 25+ years in accounting profession • Executive Director, Goldman Sachs • Partner, Vistra • Director, KPMG Consulting, Senior Manager KPMG • CFO and
Slide 11: The Way Forward: Pathway to Clinical Trials
THE WAY FORWARD PATHWAY TO CLINICAL TRIALS For personal use only Invion is building on early successes by identifying target cancer indications with our partner institutions whilst making pre-clinical preparations with a view to initiating clinical trials in more than one indication in 2022. 1H 2022
Slide 12: Market Overview
Price and Volume MARKET OVERVIEW $0.030 Invion Limited (ASX:IVX) - Volume Invion Limited (ASX:IVX) - Share 500mm $0.025 Pricing 400mm For personal use only $0.018 Share Price Volume $0.020 300mm (at 2nd February 2022) $0.015 200mm Market Cap $0.010 100mm A$115m $0.005 0 1 2 1 21 21 21 21 21 1 1 21 2
Slide 13: For personal use only
For personal use only